FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293113> ?p ?o ?g. }

• W4286293113 endingPage "e24083" @default.
• W4286293113 startingPage "e24083" @default.
• W4286293113 abstract "e24083 Background: EGFRi’s are associated with dermatologic AEs that include an acneiform skin rash. This rash occurs in up to 80% for all grades and 18% for grades ≥3. Treatments are based on grade and include topical antibiotics or corticosteroids for grades 1 and 2, and EGFRi dose interruption and/or oral corticosteroids for severe grades (i.e., ≥ grade 3). For prevention, topical corticosteroids or oral antibiotics are recommended. This survey was conducted to assess current toxicity management patterns and treatment gaps for EGFRi associated skin rash. Methods: An online survey (MedSurvey) with 5 eligibility & 8 questions related to EGFRi practice patterns was conducted (April 2021). Fifty-one practicing oncologists completed the survey. Results: Among the 51 oncologists, 86% have been practicing ≥ 11 yrs with 37% from an academic and 63% from a community setting. They (percent of respondents) prescribed cytotoxic chemotherapy (91%) and targeted agents (84%) > 10x/week. Prevention of EGFRi skin rash with topical antibiotics (33%), topical steroids (45%), and oral antibiotics (45%) were commonly administered prophylactic treatments, while 26% do not treat prophylactically. EGFRi’s were started at a lower dose always 6%, frequently (≥50%) 26%, sometimes (< 50%) 24%, and never 45% of the time. Skin rash treatment is started by 47% at Grade 1, 33% at Grade 2, and 2% ≥Grade 3, while 18% start treatment prophylactically. The majority (57%) would use a novel agent to treat skin rash, while 26% would use it for patients with a previous occurrence, 13% for those not responding to the standard of care and 2% would use this agent for selected EGFR inhibitors. For Grade 1 skin rash (multiple choices allowed), 33% used observation only for management, whereas 55% prescribed topical antibiotics, 35% prescribed oral antibiotics, and 55% used topical steroids. Dose reduction was implemented 4% of the time. For Grade 2 skin rash (multiple choices allowed) 51% used topical antibiotics, 63% prescribed an oral antibiotic, and 77% used topical steroids. Dose reduction was used 35% of the time. For patients not responding to standard therapy 6% switched to a different anti-cancer regimen, 16% changed to another EGFRi, while 77% interrupted the EGFRi therapy. Conclusions: Treating EGFRi-associated skin rash continues to be a significant challenge with Grade 2/3 toxicity or patients not responding to standard treatment. This often requires a therapeutic dose reduction or interruption that may impact the efficacy of anti-cancer treatment. Effective management (prevention and treatment) for skin toxicities associated with EGFRi inhibitors remains an unmet need for many patients and a treatment challenge for oncologists." @default.
• W4286293113 created "2022-07-21" @default.
• W4286293113 creator A5002599922 @default.
• W4286293113 creator A5003779761 @default.
• W4286293113 creator A5014723591 @default.
• W4286293113 creator A5019406303 @default.
• W4286293113 creator A5044963977 @default.
• W4286293113 creator A5051149549 @default.
• W4286293113 creator A5052375254 @default.
• W4286293113 creator A5059219836 @default.
• W4286293113 creator A5069841884 @default.
• W4286293113 creator A5071784712 @default.
• W4286293113 creator A5087679575 @default.
• W4286293113 creator A5088155455 @default.
• W4286293113 creator A5088282123 @default.
• W4286293113 date "2022-06-01" @default.
• W4286293113 modified "2023-10-16" @default.
• W4286293113 title "A survey study of prevention and treatment patterns by academic and community oncologists for papulopustular, acneiform skin rash associated with epidermal growth factor receptor inhibitor (EGFRi) therapy." @default.
• W4286293113 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e24083" @default.
• W4286293113 hasPublicationYear "2022" @default.
• W4286293113 type Work @default.
• W4286293113 citedByCount "0" @default.
• W4286293113 crossrefType "journal-article" @default.
• W4286293113 hasAuthorship W4286293113A5002599922 @default.
• W4286293113 hasAuthorship W4286293113A5003779761 @default.
• W4286293113 hasAuthorship W4286293113A5014723591 @default.
• W4286293113 hasAuthorship W4286293113A5019406303 @default.
• W4286293113 hasAuthorship W4286293113A5044963977 @default.
• W4286293113 hasAuthorship W4286293113A5051149549 @default.
• W4286293113 hasAuthorship W4286293113A5052375254 @default.
• W4286293113 hasAuthorship W4286293113A5059219836 @default.
• W4286293113 hasAuthorship W4286293113A5069841884 @default.
• W4286293113 hasAuthorship W4286293113A5071784712 @default.
• W4286293113 hasAuthorship W4286293113A5087679575 @default.
• W4286293113 hasAuthorship W4286293113A5088155455 @default.
• W4286293113 hasAuthorship W4286293113A5088282123 @default.
• W4286293113 hasConcept C16005928 @default.
• W4286293113 hasConcept C2777673923 @default.
• W4286293113 hasConcept C2778081122 @default.
• W4286293113 hasConcept C2778570526 @default.
• W4286293113 hasConcept C2778847519 @default.
• W4286293113 hasConcept C501593827 @default.
• W4286293113 hasConcept C71924100 @default.
• W4286293113 hasConcept C86803240 @default.
• W4286293113 hasConcept C89423630 @default.
• W4286293113 hasConceptScore W4286293113C16005928 @default.
• W4286293113 hasConceptScore W4286293113C2777673923 @default.
• W4286293113 hasConceptScore W4286293113C2778081122 @default.
• W4286293113 hasConceptScore W4286293113C2778570526 @default.
• W4286293113 hasConceptScore W4286293113C2778847519 @default.
• W4286293113 hasConceptScore W4286293113C501593827 @default.
• W4286293113 hasConceptScore W4286293113C71924100 @default.
• W4286293113 hasConceptScore W4286293113C86803240 @default.
• W4286293113 hasConceptScore W4286293113C89423630 @default.
• W4286293113 hasIssue "16_suppl" @default.
• W4286293113 hasLocation W42862931131 @default.
• W4286293113 hasOpenAccess W4286293113 @default.
• W4286293113 hasPrimaryLocation W42862931131 @default.
• W4286293113 hasRelatedWork W1562571209 @default.
• W4286293113 hasRelatedWork W2001105285 @default.
• W4286293113 hasRelatedWork W2007540203 @default.
• W4286293113 hasRelatedWork W2087948898 @default.
• W4286293113 hasRelatedWork W2128434532 @default.
• W4286293113 hasRelatedWork W2547152897 @default.
• W4286293113 hasRelatedWork W2564643150 @default.
• W4286293113 hasRelatedWork W2599753304 @default.
• W4286293113 hasRelatedWork W2884243983 @default.
• W4286293113 hasRelatedWork W775482203 @default.
• W4286293113 hasVolume "40" @default.
• W4286293113 isParatext "false" @default.
• W4286293113 isRetracted "false" @default.
• W4286293113 workType "article" @default.